Literature DB >> 32591868

Use of platelet-rich fibrin for the treatment of gingival recessions: a systematic review and meta-analysis.

Richard J Miron1, Vittorio Moraschini2, Massimo Del Fabbro3,4, Adriano Piattelli5,6,7, Masako Fujioka-Kobayashi8, Yufeng Zhang9, Nikola Saulacic8, Benoit Schaller8, Tomoyuki Kawase10, Raluca Cosgarea11,12, Soren Jepsen12, Delia Tuttle13, Mark Bishara14, Luigi Canullo15, Meizi Eliezer16, Andreas Stavropoulos17, Yoshinori Shirakata18, Alexandra Stähli16, Reinhard Gruber19, Ondine Lucaciu11, Sofia Aroca16, Herbert Deppe20, Hom-Lay Wang21, Anton Sculean16.   

Abstract

OBJECTIVES: The aim of this systematic review and meta-analysis was to compare the use of platelet-rich fibrin (PRF) with other commonly utilized treatment modalities for root coverage procedures.
MATERIALS AND METHODS: The eligibility criteria comprised randomized controlled trials (RCTs) comparing the performance of PRF with that of other modalities in the treatment of Miller class I or II (Cairo RT I) gingival recessions. Studies were classified into 5 categories as follows: (1) coronally advanced flap (CAF) alone vs CAF/PRF, (2) CAF/connective tissue graft (CAF/CTG) vs CAF/PRF, (3) CAF/enamel matrix derivative (CAF/EMD) vs CAF/PRF, (4) CAF/amnion membrane (CAF/AM) vs CAF/PRF, and (5) CAF/CTG vs CAF/CTG/PRF. Studies were evaluated for percentage of relative root coverage (rRC; primary outcome), clinical attachment level (CAL), keratinized mucosa width (KMW), and probing depth (PD) (secondary outcomes).
RESULTS: From 976 articles identified, 17 RCTs were included. The use of PRF statistically significantly increased rRC and CAL compared with CAF alone. No change in KMW or reduction in PD was reported. Compared with PRF, CTG resulted in statistically significantly better KMW and RC. No statistically significant differences were reported between the CAF/PRF and CAF/EMD groups or between the CAF/PRF and CAF/AM groups for any of the investigated parameters.
CONCLUSIONS: The use of CAF/PRF improved rRC and CAL compared with the use of CAF alone. While similar outcomes were observed between CAF/PRF and CAF/CTG for CAL and PD change, the latter group led to statistically significantly better outcomes in terms of rRC and KTW. In summary, the use of PRF in conjunction with CAF may represent a valid treatment modality for gingival recessions exhibiting adequate baseline KMW. CLINICAL RELEVANCE: The data indicate that the use of PRF in conjunction with CAF statistically significantly improves rRC when compared with CAF alone but did not improve KMW. Therefore, in cases with limited baseline KMW, the use of CTG may be preferred over PRF.

Entities:  

Keywords:  Gingival recession; L-PRF; Periodontal plastic surgery; Platelet-rich fibrin

Mesh:

Year:  2020        PMID: 32591868     DOI: 10.1007/s00784-020-03400-7

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.573


  17 in total

1.  The effect of resting and compression time post-centrifugation on the characteristics of platelet rich fibrin (PRF) membranes.

Authors:  Yan Wei; Yihong Cheng; Yulan Wang; Xiaoxin Zhang; Richard J Miron; Yufeng Zhang
Journal:  Clin Oral Investig       Date:  2022-04-22       Impact factor: 3.606

Review 2.  Is the use of platelet-rich fibrin effective in the healing, control of pain, and postoperative bleeding in the palatal area after free gingival graft harvesting? A systematic review of randomized clinical studies.

Authors:  Jonathan Meza-Mauricio; Camila Pinheiro Furquim; Antonella Geldres; Gerardo Mendoza-Azpur; Belen Retamal-Valdes; Vittorio Moraschini; Marcelo Faveri
Journal:  Clin Oral Investig       Date:  2021-04-07       Impact factor: 3.573

Review 3.  Moving toward targeting the right phenotype with the right platelet-rich plasma (PRP) formulation for knee osteoarthritis.

Authors:  Isabel Andia; Leire Atilano; Nicola Maffulli
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-03-29       Impact factor: 5.346

4.  Platelet rich fibrin as a gingival tissue regeneration enhancer.

Authors:  Bianca Nausica Petrescu; Ioana Codruta Mirica; Richard Miron; Radu Septimiu Campian; Ondine Lucaciu
Journal:  J Dent Sci       Date:  2020-09-08       Impact factor: 2.080

Review 5.  Use of platelet-rich fibrin for the treatment of periodontal intrabony defects: a systematic review and meta-analysis.

Authors:  Richard J Miron; Vittorio Moraschini; Masako Fujioka-Kobayashi; Yufeng Zhang; Tomoyuki Kawase; Raluca Cosgarea; Soren Jepsen; Mark Bishara; Luigi Canullo; Yoshinori Shirakata; Reinhard Gruber; Döri Ferenc; Monica Diuana Calasans-Maia; Hom-Lay Wang; Anton Sculean
Journal:  Clin Oral Investig       Date:  2021-02-20       Impact factor: 3.573

Review 6.  Platelet-Rich Fibrin in Single and Multiple Coronally Advanced Flap for Type 1 Recession: An Updated Systematic Review and Meta-Analysis.

Authors:  Leonardo Mancini; Francesco Tarallo; Vincenzo Quinzi; Adriano Fratini; Stefano Mummolo; Enrico Marchetti
Journal:  Medicina (Kaunas)       Date:  2021-02-05       Impact factor: 2.430

7.  Liquid PRF Reduces the Inflammatory Response and Osteoclastogenesis in Murine Macrophages.

Authors:  Zahra Kargarpour; Jila Nasirzade; Layla Panahipour; Richard J Miron; Reinhard Gruber
Journal:  Front Immunol       Date:  2021-04-09       Impact factor: 8.786

Review 8.  Recent Advances in Vertical Alveolar Bone Augmentation Using Additive Manufacturing Technologies.

Authors:  Cedryck Vaquette; Joshua Mitchell; Sašo Ivanovski
Journal:  Front Bioeng Biotechnol       Date:  2022-02-07

9.  Platelet-Rich Fibrin Decreases the Inflammatory Response of Mesenchymal Cells.

Authors:  Zahra Kargarpour; Jila Nasirzade; Layla Panahipour; Richard J Miron; Reinhard Gruber
Journal:  Int J Mol Sci       Date:  2021-10-20       Impact factor: 6.208

10.  Platelet-Rich Fibrin Increases BMP2 Expression in Oral Fibroblasts via Activation of TGF-β Signaling.

Authors:  Zahra Kargarpour; Jila Nasirzade; Layla Panahipour; Goran Mitulović; Richard J Miron; Reinhard Gruber
Journal:  Int J Mol Sci       Date:  2021-07-25       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.